Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors

Sonidegib is a selective inhibitor of Smoothened receptor, which is a key regulator of the Hedgehog signaling pathway. The purpose of this study was to determine the maximum tolerated dose based on dose‐limiting toxicity (DLT) and the recommended dose (RD) of sonidegib in Asian patients with advance...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Minami, Hironobu, Ando, Yuichi, Ma, Brigette Buig Yue, Hsiang Lee, Jih‐, Momota, Hiroyuki, Fujiwara, Yutaka, Li, Leung, Fukino, Koichi, Ito, Koji, Tajima, Takeshi, Mori, Asuka, Lin, Chia‐Chi
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084670/
https://ncbi.nlm.nih.gov/pubmed/27467121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13022
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars